Therapeutics company Titan Pharmaceuticals Inc (NASDAQ:TTNP) stated on Monday its net loss of USD9.3m (USD1.64 per common share) for the full year ended 31 December 2018.
This reflects a growth when compared with a higher net loss of USD14.3m (USD4.05 per common share) for 2017.
Total revenues of USD6.6m were generated for the full year ended 31 December 2018, arise over total revenues of USD0.2m in 2017.
R&D expenses of USD7.5m were recorded for the year ended 31 December 2018, a decline from R&D of USD9.6m in 2017.
The company added that the drop in R&D costs was primarily associated with decreases in external R&D expenses related to the support of ProNeura product development programmes, employee related expenses and other R&D expenses.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva